Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group

  • Published : 2012.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: An association between the ABO blood group and the risk of certain malignancies, including pancreatic and gastric cancer, has been reported previously. However, it is unclear whether this association is valid for gastrointestinal stromal tumors (GIST). In this study, ABO blood groups and the Rh factor were investigated in a series of GIST cases. Material and Methods: In 162 patients with GIST, blood group and Rh factor were examined and compared with a control group of 3,022,883 healthy volunteer blood donors of the Turkish Red Crescent between 2004 and 2011. The relationship of blood groups with tumor size, mitotic activity, and age were also evaluated. Results: Overall, the ABO blood group and Rh factor distributions of the 162 patients with GIST were similar to those of the general population. There were no significant differences between both ABO blood types and Rh factor in terms of tumor size, mitotic activity, and age. Conclusion: This is the first study reported on this issue. In our study, we didn't find any relationship between GIST and ABO blood group and Rh factor. However further studies with larger number of patients are needed to establish the role of blood groups in this population.

Keywords

References

  1. Aird I, Bentall HH, Roberts JA (1953). A relationship between cancer of stomach and the abo blood groups. Br Med J, 1, 799-801. https://doi.org/10.1136/bmj.1.4814.799
  2. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al (2009). Genome-wide association study identifies variants in the abo locus associated with susceptibility to pancreatic cancer. Nat Genet, 41, 986-90. https://doi.org/10.1038/ng.429
  3. Blanke CD, Rankin C, Demetri GD, et al (2008). Phase iii randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26, 626-32. https://doi.org/10.1200/JCO.2007.13.4452
  4. Casali PG, Blay JY (2010). Gastrointestinal stromal tumours: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 98-102. https://doi.org/10.1093/annonc/mdp496
  5. Corless CL, Barnett CM, Heinrich MC (2011). Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer, 11, 865-78. https://doi.org/10.1038/nrc3143
  6. Dall'olio F (1996). Protein glycosylation in cancer biology: An overview. Clin Mol Pathol, 49, 126-35. https://doi.org/10.1136/mp.49.3.M126
  7. Debiec-Rychter M, Sciot R, Le Cesne A, et al (2006). Kit mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 42, 1093-103. https://doi.org/10.1016/j.ejca.2006.01.030
  8. Demetri GD, van Oosterom AT, Garrett CR, et al (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet, 368, 1329-38. https://doi.org/10.1016/S0140-6736(06)69446-4
  9. Demetri GD, von Mehren M, Blanke CD, et al (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, 472-80. https://doi.org/10.1056/NEJMoa020461
  10. Edgren G, Hjalgrim H, Rostgaard K, et al (2010). Risk of gastric cancer and peptic ulcers in relation to abo blood type: a cohort study. Am J Epidemiol, 172, 1280-5. https://doi.org/10.1093/aje/kwq299
  11. Greer JB, Yazer MH, Raval JS, et al (2010). Significant association between abo blood group and pancreatic cancer. World J Gastroenterol, 16, 5588-91. https://doi.org/10.3748/wjg.v16.i44.5588
  12. Heinrich MC, Corless CL, Demetri GD, et al (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21, 4342-9. https://doi.org/10.1200/JCO.2003.04.190
  13. Heinrich MC, Owzar K, Corless CL, et al (2008). Correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by cancer and leukemia group b and southwest oncology group. J Clin Oncol, 26, 5360-7. https://doi.org/10.1200/JCO.2008.17.4284
  14. Hirota S, Isozaki K, Moriyama Y, et al (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577-80. https://doi.org/10.1126/science.279.5350.577
  15. Hosoi E (2008). Biological and clinical aspects of abo blood group system. J Med Invest, 55, 174-82. https://doi.org/10.2152/jmi.55.174
  16. Iodice S, Maisonneuve P, Botteri E, et al (2010). Abo blood group and cancer. Eur J Cancer, 46, 3345-50. https://doi.org/10.1016/j.ejca.2010.08.009
  17. Mazur MT, Clark HB (1983). Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 7, 507-19. https://doi.org/10.1097/00000478-198309000-00001
  18. Wolpin BM, Chan AT, Hartge P, et al (2009). Abo blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31. https://doi.org/10.1093/jnci/djp020

Cited by

  1. Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract vol.1, pp.6, 2013, https://doi.org/10.3892/mco.2013.181